Showing 34,181 - 34,200 results of 34,844 for search '(( 50 ((a decrease) OR (nn decrease)) ) OR ( e ((fold decrease) OR (point decrease)) ))', query time: 0.90s Refine Results
  1. 34181

    Supplemental Material for Juurakko et al., 2021 by Collin L. Juurakko (10941459)

    Published 2021
    “…</p><p></p><p></p><p> </p><p>A list of protein accession identifications for all significantly increased and decreased proteins obtained by MS were assembled and used as inputs for STRING (version 11.0) to predict protein-protein interactions (Franceschini <i>et al.…”
  2. 34182
  3. 34183

    Mean response rate indicating the velocity of illusory movement, Run 1 and Run 2 combined data (N = 12). by Tatjana Seizova-Cajic (80195)

    Published 2013
    “…The velocity computed this way steadily decreases throughout the vibration period. <i>Triangles</i>: Means were computed only for periods in which movement was perceived (i.e., zeros were excluded) separately for illusory extension (positive sign) and flexion (negative sign). …”
  4. 34184

    Epileptiform activity induces opposite changes in the RRP and P<sub>rel.</sub> by Carlo Natale Giuseppe Giachello (380180)

    Published 2013
    “…<p>(A,B) Cumulative curves of EPSP amplitudes evoked at 10 Hz at different time-points. The linear part was fitted as described in Methods. …”
  5. 34185

    Perfusion of substance P (15 μM) had no effect on the amplitude or slope of the fEPSP recorded from the CA1 region of the rat hippocampal slice by Kerrie N Wease (12951)

    Published 2011
    “…(b) and (c) Pooled time course data showing the lack of effect of substance P on the slope (b) and amplitude (c) of the fEPSP. Points represent mean ± s.e.m., n = 4. Scale bar represents 0.5 mV and 10 ms.…”
  6. 34186

    Transcriptional response of components of the Cu efflux network and phenotypic consequences of their deletion. by W. Lee Pang (102290)

    Published 2013
    “…Expression of the metalloregulator <i>VNG1179C</i> does not change, suggesting that it is post-transcriptionally activated. Error bars are s.e.m for n = 5. Points (X) within each expression profile were normalized to the expression value at t = 0 (X<sub>0</sub>). …”
  7. 34187

    PTEN expression in mitochondrial and cytosolic fraction after the excitotoxic stimulus. by Valentina Grande (647515)

    Published 2014
    “…Data are expressed as mean ± S.E.M., *<i>P</i><0.05, #<i>P</i><0.05, **<i>P</i><0.01 with Two way ANOVA and Bonferroni post hoc test. …”
  8. 34188
  9. 34189

    The effect of ranibizumab and aflibercept injected intraperitoneally into neonatal mice. by Yusuke Ichiyama (11237783)

    Published 2022
    “…(F-I) The high magnification images of the whole-mounted retinas show decreased number of branching points, increased area of regressed capillaries (filled arrowheads), and decreased number of proliferating ECs (open arrowheads) in the aflibercept group but not in the ranibizumab groups. …”
  10. 34190

    G-chart of Diagnosis Dates of Cancer. by Harald Schrem (578639)

    Published 2016
    “…Cases marked by the letter “B” and a red dot on the lower control limit (LCL) indicate a failed Benneyan test pointing to statistically relevant increases in the diagnostic event rate which should trigger clinical concerns in regard to causation, e.g. by intensified or uncontrolled immunosuppression. …”
  11. 34191
  12. 34192
  13. 34193
  14. 34194

    <strong>Bull trout streamflow and temperature linear SCR model</strong> by Patti Wohner (16398345)

    Published 2023
    “…These extremes provided a unique opportunity to retrospectively compare bull trout survival and migration under potential climate change scenarios. …”
  15. 34195

    Reconstructing the cochlear spectrograms from firing rates. by Florian Blättler (201240)

    Published 2011
    “…This fraction decreases to 0.1% at about . (E) The reconstruction errors averaged over different stimulus ensembles are monotonic functions of the firing threshold. …”
  16. 34196
  17. 34197

    Quantitative morphometric and immunohistochemical analysis of neointima formation and RanGAP1 expression in the rat carotid artery injury model. by Marc Vorpahl (591604)

    Published 2014
    “…RanGAP1 expression in the media was the highest at the initiation of cellular proliferation and decreased to barely detectable levels at the completion of neointima formation (C). 3 days post injury, almost all cells in the neointima stained positive for RanGAP1 and subsequently, levels decrementally decreased at later time points, e.g. at day 7 and day 14 (D). …”
  18. 34198

    IL-6Rα antibodies diminish anesthetic DILI in female BALB/c mice. by Joonhee Cho (399792)

    Published 2013
    “…(A) IL-6Rα antibodies administered days 0 and 7 diminished hepatitis as demonstrated by decreased inflammation/injury scores (1.6±0.1, mean ± SE) when compared to TFA-S100 – immunized, female , BALB/c mice not treated with IL-6Rα but administered phosphate buffered saline at the same time points (2.3±0.2, mean ± SE). …”
  19. 34199

    Table_8_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX by Huiling Zheng (49699)

    Published 2024
    “…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”
  20. 34200

    Table_1_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

    Published 2024
    “…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”